Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC
Authors:
- Vaia FlorouVFVaia Florou
- Andrew ElliottAEAndrew Elliott
- Matthew H. BaileyMBMatthew H. Bailey
- David StoneDSDavid Stone
- Kajsa AffolterKAKajsa Affolter
- Heloisa P. SoaresHSHeloisa P. Soares
- Chris Nevala-PlagemannCNChris Nevala-Plagemann
- Courtney ScaifeCSCourtney Scaife
- Phillip WalkerPWPhillip Walker
- W. Michael KornWKW. Michael Korn
- Emil LouELEmil Lou
- Rachna T. ShroffRSRachna T. Shroff
- 2 June 2023
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 29 (17) , 3408-3417
Abstract
Purpose: Pure pancreatic acinar cell carcinomas (PACC) are rare malignancies with no established treatment. PACC demonstrates significant genetic intertumoral heterogeneity with multiple pathways involved, suggesting using targeted cancer therapeutics to treat this disease. We aggregated one of the largest datasets of pure PACC to examine the genomic variability and explore patient-specific therapeutic targets. Experimental Design: PACC specimens (n = 51) underwent next-generation sequencing of DNA (n = 29) or whole exome (n = 22) and RNA (whole transcriptome, n = 29) at a commercial laboratory. We performed comparative analyses of a genomic cohort of pancreatic ductal adenocarcinomas (PDAC; n = 4,205). In parallel, we conducted a retrospective review of patients with PACC treated at Huntsman Cancer Institute (HCI). Results: The real-world dataset included samples from 51 patients with PACC. We found key molecular differences between pure PACC and PDAC, highlighting the unique characteristics of pure PACC. Major differences in PACC include lower MAPK signaling and less stromal cell abundance compared with PDAC. Pure PACC showed genomic loss-of-heterozygosity to largely coincide with mutations in BRCA1, BRCA2, and PALB2. Of the 7 patients treated at HCI, one had a tumor that harbored a BRAF-V600E mutation. Leveraging precision oncology, this patient is being treated with encorafenib plus binimetinib, achieving an exceptionally durable and ongoing complete response of more than 3 years. Conclusions: There are major differences between PACC and PDAC, including downregulation of the MAPK signaling pathway, and less stromal cell abundance. In addition, genomic characterization of pure PACC revealed frequent targetable alterations, which can guide patient treatment.Keywords
All Related Versions
Funding Information
- National Institutes of Health (P30CA042014)
This publication has 25 references indexed in Scilit:
- BRCAness revisitedNature Reviews Cancer, 2016
- Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomasNature Genetics, 2015
- Whole exome sequencing reveals recurrent mutations in BRCA2 and FAT genes in acinar cell carcinomas of the pancreasScientific Reports, 2015
- Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair GenesCancer Discovery, 2014
- Whole‐exome sequencing of pancreatic neoplasms with acinar differentiationThe Journal of Pathology, 2013
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 2012
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- Acinar Cell Carcinoma of the Pancreas in the United States: Prognostic Factors and Comparison to Ductal AdenocarcinomaJournal of Gastrointestinal Surgery, 2008
- 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinomaSurgery, 2008
- Acinar Cell Carcinoma of the PancreasPancreas, 2007